Financial Data and Key Metrics Changes - For fiscal year 2025, the company reduced its operating loss by $1.2 million to approximately $2.1 million, marking the third consecutive year of improved operating results [4] - Adjusted non-GAAP EBITDA improved from a $1.7 million loss in 2024 to a $900,000 loss in 2025, driven by disciplined cost control and efficient marketing spend [4][15] - Total net sales for fiscal year 2025 were $19.1 million, a slight decrease from $19.5 million in the prior year [10] - Gross profit as a percentage of net sales increased to 63% for fiscal 2025, compared to 62% in the previous year [12] Business Line Data and Key Metrics Changes - E-commerce direct-to-consumer sales for the fourth quarter of fiscal 2025 were $3.5 million, a 6% year-over-year decrease, representing 75.1% of total net sales for that quarter [10] - The wholesale business generated $1.2 million in net sales for the fourth quarter of fiscal 2025, up 25% from $900,000 in the same quarter of fiscal 2024 [11] - The company focused on SKU rationalization and prioritizing higher velocity products across its core brands, which helped stabilize the business while maintaining strong gross margins [5] Market Data and Key Metrics Changes - The company has distribution across nine states for its new beverage brand, Oasis, and is evaluating additional markets [4] - The executive order from the White House regarding federal cannabis policy is expected to positively impact the hemp and CBD industry, potentially increasing demand for quality products [8][30] Company Strategy and Development Direction - The company is focused on scaling the Oasis brand responsibly while driving efficient, profitable direct-to-consumer growth through disciplined marketing execution [17] - The management aims to preserve margins and capital discipline while evaluating strategic opportunities aligned with regulatory strength [17] - The company believes it is well-positioned to benefit from improving regulatory clarity and is committed to maintaining a strong, flexible balance sheet [9][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's direction, highlighting lower operating losses and restored exchange compliance as key achievements [3][17] - The potential for significant demand increase due to Medicare reimbursement pathways for CBD products was noted, with estimates suggesting a $30 billion market opportunity [17][30] - The management emphasized the importance of navigating regulatory changes carefully while continuing to build a profitable long-term organization [30][44] Other Important Information - The company received confirmation from the NYSE American that all prior compliance deficiencies had been resolved, reflecting progress in restoring financial stability [7] - The company closed $2.25 million in additional financing, enhancing its liquidity position [5][16] Q&A Session Summary Question: What will be the key driver of growth in 2026? - Management indicated that both the core cbdMD brand and the Oasis beverage line have significant growth opportunities, with a focus on regulatory developments [20][22] Question: What caused the decline in direct-to-consumer sales? - Management explained that the decline was tied to organizational changes and SKU reductions, but noted a slight upward trend in the D2C business over the past 24 months [23][24] Question: What is the timeline for Medicare coverage of CBD products? - Management mentioned that a pilot program is expected to start on April 1st, with potential for significant demand increase for quality products [25][30] Question: How will the executive order impact the business? - Management believes the executive order could lead to a substantial increase in demand for CBD products, although the details of implementation are still being assessed [29][30] Question: How will the company prioritize growth investments in 2026? - Management indicated that for the next quarter, investment will be more weighted towards the Oasis side, with ongoing evaluations based on regulatory developments [46][48] Question: What is the current share count and any new executive compensation plans? - Management provided the current share count and mentioned that a new employee compensation plan is subject to shareholder vote in the upcoming annual meeting [49][52]

Core Insights - The recent executive order by President Trump marks a significant step in cannabis policy reform, although it does not legalize cannabis, it facilitates medical research and alleviates the tax burden on companies in the industry [1][2] - The executive order is seen as a precursor to further legislative actions, particularly regarding safer banking for cannabis businesses, which could lead to greater access to capital and potential listings on major US exchanges like NASDAQ and NYSE [3][4] Industry Impact - The cannabis industry has faced significant challenges, including a 20% market sell-off following a 150% increase in five days, indicating volatility and market reactions to news [5] - There is a concern regarding the relationship between the cannabis and hemp markets, particularly in light of the new regulations and the need for a regulated marketplace [5][6] - The executive order emphasizes the importance of safe, regulated, and tested products, aligning with the existing medical cannabis programs in 40 states [7][8]

Group 1 - The U.S. federal government is considering a significant policy shift to lower the regulatory classification of cannabis from a Schedule I substance to a Schedule III substance, aligning it with common prescription painkillers [1] - Currently, cannabis is classified as a Schedule I substance, indicating high abuse potential and no accepted medical use, similar to heroin and LSD [1] - The proposed change would recognize cannabis as having a lower abuse risk and potential medical applications, similar to medications like Tylenol with codeine and certain steroids [1] Group 2 - Relevant A-share concept stocks include companies such as Chenguang Biotech and Fuan Pharmaceutical, which may benefit from the potential regulatory changes in cannabis [2]